Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Other Non Operating Income (2019 - 2025)

Rein Therapeutics (RNTX) has disclosed Other Non Operating Income for 7 consecutive years, with -$65000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income rose 83.5% to -$65000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3000.0 through Dec 2025, down 84.21% year-over-year, with the annual reading at $3000.0 for FY2025, 84.21% down from the prior year.
  • Other Non Operating Income for Q4 2025 was -$65000.0 at Rein Therapeutics, up from -$89000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $336000.0 in Q4 2022, with the low at -$394000.0 in Q4 2024.
  • Average Other Non Operating Income over 5 years is $73611.1, with a median of $81500.0 recorded in 2021.
  • The sharpest move saw Other Non Operating Income skyrocketed 3800.0% in 2023, then crashed 704.08% in 2024.
  • Over 5 years, Other Non Operating Income stood at $71000.0 in 2021, then skyrocketed by 373.24% to $336000.0 in 2022, then tumbled by 114.58% to -$49000.0 in 2023, then plummeted by 704.08% to -$394000.0 in 2024, then skyrocketed by 83.5% to -$65000.0 in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at -$65000.0, -$89000.0, and $49000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.